Q-omics provides the consensus-scored COQ10BP2 profile across patient tissues and cancer cell-line models. COQ10BP2 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, COQ10BP2 is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, COQ10BP2 RNA expression shows 7,386 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight UCS, BRCA, and LAML as cancer lineages where COQ10BP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COQ10BP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COQ10BP2 survival associations across molecular data types. COQ10BP2 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COQ10BP2 RNA expression–survival associations across cancer types. High COQ10BP2 expression shows unfavorable associations in UCS, SKCM, READ and LIHC, but favorable associations in UCEC and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for COQ10BP2 RNA expression.
This table summarizes COQ10BP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for COQ10BP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COQ10BP2 shows higher tumor expression in BRCA, KICH, LIHC and THCA. The BRCA box plot shows higher COQ10BP2 RNA expression in tumor versus normal tissue (log2 FC = +0.107, t-test p = .040).
This table shows molecular features associated with COQ10BP2 in patient tissues and cancer cell lines. In patient samples, COQ10BP2 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
